BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, May 14, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 22, 2005
View Archived Issues
RG-108 reactivates tumor suppressor genes by reverting epigenetic mutations in cancer cells
Read More
In vitro antiangiogenic actions of pasireotide compared to octreotide
Read More
Transferrin receptor revealed as a novel cancer target
Read More
New data on the antitumor effects and safety of ZD-6474 in solid malignancies
Read More
Response to HSPPC-96 is not affected by cytokines in advanced melanoma patients
Read More
ADAM33 gene involved in embryonic airway development and determines severity of COPD
Read More
QR-333 safely reduces symptoms of diabetic peripheral neuropathy
Read More
Pegvisomant treatment benefits patients with acromegaly
Read More
Bosentan shows efficacy in stabilizing disease in patients with advanced melanoma
Read More
New phase II data supports the use of Rambazole in acne
Read More
Snapshots on pregabalin in epilepsy and neuropathic pain
Read More
Novagali Pharma completes initial clinical evaluation of proprietary oral paclitaxel
Read More
Novartis reports promising phase III data with SPP-100 for hypertension
Read More
Cytheris initiates additional phase I/II trial with recombinant interleukin-7
Read More
FDA grants full approval to Arimidex for treatment of postmenopausal breast cancer
Read More
The Immune Response Corporation reports update on HIV and MS clinical programs
Read More
Curis and Procter & Gamble collaborate on hair growth program
Read More
NeuTec Pharma to evaluate Mycograb for breast cancer
Read More
Tachykinin antagonists prepared and tested at Takeda
Read More
Celera begins phase I clinical evaluation of cathepsin S inhibitor for psoriasis
Read More
Celtic Pharma acquires worldwide rights to Xerecept
Read More
Isis begins phase II development of second-generation antisense drug for high cholesterol
Read More
Medicure receives FDA fast track designation for MC-1
Read More
Novel antidiabetic agents disclosed in recent patent literature
Read More
Pfizer receives nonapprovable letter in U.S. for COX-2 inhibitor for acute pain
Read More
UCB's antiepileptic Keppra approved in E.U.
Read More
Novartis reports phase III data and update of R&D pipeline
Read More
Anti-HEH4 antibodies claimed for bone or cartilage-related disorders
Read More